Trials / Sponsors / Spruce Biosciences

Spruce Biosciences

Industry · 6 registered clinical trials.

Status	Trial	Phase	Started
Terminated	A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Polycystic Ovary Syndrome	Phase 2	2022-05-15
Terminated	A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH Congenital Adrenal Hyperplasia, 21-OHD	Phase 2	2021-12-10
Terminated	A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH Congenital Adrenal Hyperplasia	Phase 2	2021-02-22
Terminated	A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH Congenital Adrenal Hyperplasia	Phase 2	2020-08-26
Completed	Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia, CAH - 21-Hydroxylase Deficiency	Phase 2	2018-09-06
Completed	Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia	Phase 2	2017-07-12